Please check your internet connection and try again.
# Methylcobalamin
## Overview
Methylcobalamin is a biologically active, coenzyme form of Vitamin B12 (cobalamin). Unlike cyanocobalamin, it does not require metabolic conversion to become active and is involved in the transfer of methyl groups in the methionine synthase reaction, facilitating DNA and protein synthesis and myelin sheath maintenance.
## Primary Indications
* Peripheral neuropathy (diabetic or toxic)
* Vitamin B12 deficiency (megaloblastic anemia)
* Adjunctive therapy in chronic neurological disorders or homocysteine elevation
* *Note: Specific approved indications vary significantly by jurisdiction/country.*
## Adult Dosing
* **Peripheral Neuropathy:** 500 mcg orally 3 times daily (1,500 mcg/day total).
* **Vitamin B12 Deficiency:** Dosing varies widely; oral supplementation may range from 1,000 mcg to 2,000 mcg daily depending on the severity of malabsorption.
* **Parenteral (IM/IV):** 500 mcg injections 1–3 times weekly based on clinical assessment and serum levels.
## Pediatric Dosing
Standardized pediatric dosing for methylcobalamin is not well established. Pediatric use should be according to institutional protocol or specialist recommendation, typically based on calculated daily requirements for Vitamin B12 (e.g., 5–30 mcg daily for infants/children depending on age and deficiency status).
## Dose Adjustments
* **Renal Impairment:** No specific adjustment required; however, monitor levels closely if chronic kidney disease is present as uremia may affect absorption/metabolism.
* **Hepatic Impairment:** Generally safe; no manufacturer-recommended dose adjustments.
## Contraindications
* Hypersensitivity to cobalt or any component of the formulation.
* Early form of Leber’s hereditary optic neuropathy (may accelerate atrophy of the optic nerve).
## Adverse Effects
* **Common:** Injection site reaction (pain, redness), headache.
* **Rare:** Anaphylaxis, hypersensitivity reactions, rash, nausea, diarrhea.
* **Metabolic:** Potential for hypokalemia during the initial phase of intensive treatment for megaloblastic anemia (due to rapid erythrocyte uptake of potassium).
## Key Drug Interactions
* **Chloramphenicol:** May decrease the hematopoietic response to methylcobalamin.
* **Metformin/PPIs/H2 Antagonists:** Chronic use may reduce the intestinal absorption of dietary/supplemental B12.
* **Colchicine/Neomycin:** May impair the absorption of Vitamin B12.
## Monitoring
* **Baseline:** Serum Vitamin B12 levels, complete blood count (CBC), and homocysteine levels.
* **During therapy:** Monitor hemoglobin, hematocrit, and mean corpuscular volume (MCV) to assess response to anemia treatment.
* **Neurological status:** Periodic reassessment of sensory/motor function for those treated for neuropathy.
## Clinical Pearls
* **Bioavailability:** Methylcobalamin is often sourced from sublingual or oral formulations; however, oral bioavailability is markedly reduced in patients with pernicious anemia or intrinsic factor deficiency/gastric resection. In such cases, parenteral administration is required to bypass the need for intrinsic factor.
* **Efficacy:** While clinically popular for nerve repair, data remains heterogeneous, and large-scale meta-analyses suggest modest efficacy for diabetic neuropathy.
* **Storage:** Light-sensitive; protect from direct light exposure to prevent degradation.
***
*Disclaimer: This information is for educational purposes and does not substitute for professional medical judgment. Always verify current prescribing information, local clinical protocols, and pharmacy guidelines before prescribing or administering medication.*
